Response to infliximab is related to disease duration in paediatric Crohn's disease

2003145 citationsJournal Article

Authors

Paolo Lionetti

F. Bronzini · Meyer Children's Hospital

Camilla Salvestrini · University of Florence

C. Bascietto · Sapienza University of Rome

Roberto Berni Canani · Federico II University Hospital

Gian Luigi De’ Angelis · University of Parma

Graziella Guariso · University of Padua

Abstract

Infliximab is a highly effective treatment in children and adolescents with both severe refractory or fistulizing Crohn's disease. Children with early Crohn's disease have a higher chance of prolonged response to infliximab than children with late Crohn's disease.

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Alimentary Pharmacology & Therapeutics

Volume 18, Issue 4, pp. 425-431

DOI: 10.1046/j.1365-2036.2003.01672.x

Field-Weighted Citation Impact: 3.78

Command Palette